Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from CanSino Biologics, Inc. Class H ( (HK:6185) ).
CanSino Biologics Inc. has received approval from China’s National Medical Products Administration for its 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13i). This vaccine, which uses advanced technology to enhance immunogenicity and safety, is the first in the company’s pneumococcal vaccine portfolio to gain such approval. The launch of PCV13i is expected to strengthen CanSino’s product portfolio and improve marketing efficiency, aligning with its existing high-end vaccine offerings.
More about CanSino Biologics, Inc. Class H
CanSino Biologics Inc. is a biotechnology company based in China, specializing in the development and production of vaccines. The company focuses on creating innovative vaccine solutions, with a market emphasis on high-end self-paid vaccines.
Average Trading Volume: 1,427,758
Technical Sentiment Signal: Buy
Current Market Cap: HK$10.6B
For detailed information about 6185 stock, go to TipRanks’ Stock Analysis page.